Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has given its approval for Teva Pharmaceutical's generic version of a treatment for occasional constipation to be marketed and distributed in the US.
Subscribe to our email newsletter
The product, polyethylene glycol 3350 NF for oral solution, is the AB-rated generic equivalent of Braintree’s Miralax for oral solution. According to Teva, total annual sales of the product are approximately $153 million.
Teva, headquartered in Israel, also recently announced that Copaxone, the company’s treatment for relapsing-remitting multiple sclerosis, posted record sales of $329 million in the first quarter ended March 31, 2006.
According to the company, Copaxone was the fastest growing multiple sclerosis therapy worldwide, with a growth of 29% in sales over the comparable quarter of 2005.
Sales of the drug in the US for the quarter increased 36% over the first quarter 2005 to $221 million. Meanwhile in Europe, sales increased by 17% over the comparable quarter of 2005, to $108 million.